Regenerative Medicine and Stem Cells Technologies

The current concepts and practice of cancer immunotherapy evolved from classical experiments that distinguished "self" from "non-self" and the finding that humoral immunity is complemented by cellular immunity.

Stem-cell research offers tremendous promise for biomedicine. It also raises vexing ethical and policy challenges. It can involve the destruction, creation and modification of human embryos, and has led to the premature marketing and use of unproven therapies.

A fall, followed by a crack - many people are no stranger to this. Broken bones are painful, but the majority heal very well. The secret lies in stem cells and bones natural ability to renew itself.

Researchers have created a method to kill cancerous tissue without causing the harmful side effects of chemotherapy.

Repairing heart tissue destroyed by a heart attack or medical condition with regenerative cells or tissues usually requires invasive open-heart surgery. But now biomedical engineering Professor Milica Radisic and her colleagues have developed a technique that lets them use a small needle to inject a repair patch, without the need to open up the chest cavity.

In the days after a heart attack, surviving patients and their loved ones can breathe a sigh of relief that the immediate danger is over—but the scar tissue that forms during the long healing process can inflict lasting damage. Too often it restricts the hearts ability to fill properly between beats, disrupting rhythm and ultimately leading to heart failure. Yet a new possible treatment may help to revitalize an injured ticker.

Lei and team used skin organoids derived from both newborn and adult skin cells. Specifically, they used progenitor cells, which are a type of cell that is more differentiated than stem cells. They dissociated these from newborn and adult skin and then transplanted them into nude mice.

The most common gene editing technique, CRISPR-Cas9, only modifies DNA. Thats helpful in most cases, but it means that you cant use it to tackle RNA-based diseases.

July 24, 2017 – New York (N.Y.) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (U CART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells. The patent will be issued on August 2, 2017.

In a scientific first, researchers have created piglets that could possibly one day provide organs for human transplants. Though the science is still early, its a big step forward in the quest to use pig organs to help the hundreds of thousands of people every year who await organ transplants.